Graphical Abstract Highlights d Thalamic neurons more potently activated indirect pathway striatal neurons in PD mice d This amplification was dependent upon striatal cholinergic interneurons (ChIs) d ChI-activated, presynaptic nicotinic receptors increased thalamic glutamate release d Suppressing this signaling pathway restored motor learning in PD mice SUMMARY
Correspondence
In Brief Tanimura et al. found that motor-learning deficits in a mouse model of PD were triggered by adaptations in the thalamostriatal circuitry. Cholinergic interneuron activation of nicotinic acetylcholine receptors on thalamostriatal axons was key to the adaptation.
INTRODUCTION
The striatum plays a key role in controlling goal-directed movements and habits (Graybiel and Grafton, 2015; Redgrave et al., 2010) . This control is mediated by two interacting populations of GABAergic spiny projection neurons (SPNs) that bidirectionally regulate the activity of basal ganglia nuclei that interface with motor-control circuits. Direct-pathway SPNs (dSPNs) project primarily to the internal segment of the globus pallidus and substantia nigra pars reticulata (SNr), directly controlling these interface nuclei, whereas indirect-pathway SPNs (iSPNs) indirectly influence them through the GABAergic neurons in the external segment of the globus pallidus (Gerfen and Surmeier, 2011) . Through this network, dSPNs are hypothesized to promote contextually appropriate actions and habits, whereas iSPNs suppress inappropriate ones (Kravitz et al., 2010) .
Efficient execution of goal-directed movements or habits requires that the excitability of dSPNs and iSPNs be 'balanced' (Calabresi et al., 2014; Kreitzer and Berke, 2011) . In Parkinson's disease (PD), the loss of appropriately timed and scaled dopaminergic signaling appears to bias the striatal network toward iSPN activity, resulting in rigidity and slowness of movement. This network bias or imbalance is widely viewed as a consequence of declining dopaminergic modulation of SPNs themselves, altering intrinsic excitability and the strength of excitatory, corticostriatal synapses (Albin et al., 1989; Day et al., 2006; Fieblinger et al., 2014; Kreitzer and Malenka, 2007; Mallet et al., 2006; Ruiz-DeDiego et al., 2015) . However, this imbalance may have network determinants as well. The striatum receives a rich glutamatergic innervtion from the thalamus, in addition to that from the cerebral cortex. This thalamostriatal projection is derived primarily from the intralaminar centrolateral nucleus (CLn) and parafascicular nucleus (PFn) (Ellender et al., 2013; Smith et al., 2004) . CLn and PFn neurons convey different types of information to the striatum and have distinctive intrastriatal connectivities (Bradfield et al., 2013; Chen et al., 2014; Ellender et al., 2013; Ichinohe et al., 2000; Kobayashi and Nakamura, 2003; Lacey et al., 2007; Matsumoto et al., 2001) . For example, like cortical neurons, CLn neurons form axospinous synapses on both iSPNs and dSPNs, whereas PFn neurons form axodendritic synapses on SPNs (Lacey et al., 2007; Smith et al., 2009 ). In addition, PFn, but not CLn, neurons robustly innervate giant aspiny cholinergic interneurons (ChIs), which then modulate a wide range of targets within the striatum, including SPNs (Consolo et al., 1996; Guo et al., 2015; Lapper and Bolam, 1992; Tanimura et al., 2018) . The PFn-ChI network has been hypothesized to ''reset'' the corticostriatal circuitry in response to salient environmental events and to promote set-shifting (Bradfield et al., 2013; Brown et al., 2010; Ding et al., 2010) .
What is less clear is whether the thalamostriatal network contributes to the imbalance in striatal efferent pathways and ChI dysfunction. Recent work argues that the PFn innervation of dSPNs is selectively downregulated in PD models (Parker et al., 2016) . Although consistent with the ''imbalance'' hypothesis, this study did not distinguish between PFn and CLn projections to the striatum and did not assess the potential role of striatal circuitry in the responsiveness of SPNs to thalamic stimulation. To fill the first gap, we applied a combinatorial genomic approach to mice that expressed Cre recombinase in CLn neurons. This allowed neighboring PFn neurons to be selectively manipulated with optogenetic and chemogenetic approaches using Cre-off expression constructs. To fill the second gap, we examined the responses of SPNs to optogenetic stimulation of PFn axons with and without propagated network activity. Our results show that, in the parkinsonian state, an imbalance does arise in the responsiveness of SPNs to PFn stimulation. However, this imbalance was not created by a change in PFn synapses on SPNs themselves, but rather by a ChI-mediated amplification of glutamate release by PFn synapses on iSPNs. This amplification was dependent upon presynaptic, a6-containing, nicotinic acetylcholine receptors (nAChRs) expressed by a distinct sub-population of PFn neurons. Suppressing the PFn pathway through ChIs or knocking down thalamic a6 mRNA attenuated the change in network activity and dramatically improved motor performance in parkinsonian mice.
RESULTS

PFn-Evoked Responses Were Larger in iSPNs from Parkinsonian Mice
Because the CLn and PFn abut one another (Van der Werf et al., 2002) , stereotaxic delivery of adeno-associated virus (AAV) vectors cannot achieve both selective-and near-complete infection of just one nucleus. Use of the Grp-KH288 transgenic mouse line overcame this problem. In these mice, Cre recombinase is expressed in CLn neurons, but not PFn neurons (Figures S1A and S1B) (Gerfen et al., 2013) . This line was crossed into transgenic mouse lines expressing either tdTomato under control of the D1 receptor promoter or enhanced green fluorescent protein (eGFP) under control of the D2 receptor promoter (Heintz, 2001) . To probe the functional connectivity of PFn neurons with SPNs, an AAV carrying a Cre-off channelrhodopsin2 (ChR2)-enhanced yellow fluorescent protein (eYFP) expression construct was stereotaxically injected into the PFn region of Grp-KH288 mice ( Figure 1A ). This resulted in ChR2-eYFP expression in a large proportion of PFn neurons (Figures 1B and S1D), but not in neighboring CLn neurons ( Figure S1C ).
To determine whether the strength of PFn connections was altered in parkinsonian mice, simultaneous whole-cell recordings were made from neighboring dSPNs and iSPNs in ex vivo brain slices and PFn axons were optically stimulated ( Figures  1C and 1D ). The amplitudes of the PFn-evoked excitatory postsynaptic currents (EPSCs) were similar in dSPNs and iSPNs from control mice ( Figures 1E and 1F ). However, in 6-OHDA-lesioned, parkinsonian mice, PFn-evoked EPSCs in iSPNs were significantly larger than those evoked in neighboring dSPNs (Figures 1E and 1F) . This change was attributed to the selective enhancement in PFn-evoked EPSCs in iSPNs, as PFn-evoked responses in dSPNs fell into the same range as those observed in control tissue ( Figure 1G ). To determine whether this shift was independent of stimulus intensity, we generated full-stimulus response plots ( Figure 1H ). In dSPNs, the PFn input-output curves in control and in parkinsonian mice were indistinguishable ( Figure 1I ). However, in iSPNs, the amplitude of the PFn-evoked EPSCs was greater at nearly all the stimulus intensities above threshold ( Figure 1J) .
What was responsible for the enhanced functional connectivity of iSPNs with PFn? A month after a near-complete, unilateral 6-OHDA lesion, there is a profound reduction in iSPN spine density and a loss of corticostriatal synapses (Day et al., 2006; Fieblinger et al., 2014; Suá rez et al., 2014) . It is possible that the axodendritic PFn synapses on iSPNs ''fill in'' the space created by this spine pruning. To test this hypothesis, a variant of the sCRACm approach (Petreanu et al., 2009 ) was used to map synaptic responses in iSPNs from Grp-KH288 mice injected with Cre-off ChR2-eYFP virus and then rendered parkinsonian (Figures S2A and S2B; see STAR Methods) . This approach provides information not only about the spatial distribution of synapses but also about their relative strength. These experiments failed to find any significant change in the spatial distribution of PFn synapses on iSPN dendrites or the strength of single-spot stimulation-evoked responses in iSPNs after 6-OHDA lesioning .
To assess PFn connectivity in another way, we labeled PFn axons and terminals by injecting an AAV carrying a synaptophysin-GFP (Meyer and Smith, 2006) into the PFn of D1-tdTomato mice. In ex vivo slices from these mice, individual iSPNs (identified by the absence of tdTomato) were filled with red Alexa 568 dye with a patch electrode, and then the region surrounding the iSPN was optically sectioned using two-photon laser-scanning microscopes (2PLSM) ( Figure S2C , left panel). Z stacks obtained in this way were analyzed offline with Imaris software to determine the number of close appositions of PFn terminals onto the dendritic shafts of filled iSPNs (Figures S2C, right panels, and S2D; see STAR Methods). As demonstrated in the sCRACm experiments, the number of PFn appositions on iSPN dendrites estimated using this approach did not differ between control and parkinsonian mice ( Figure S2E ).
Another possibility was that the strength of individual PFn-iSPN synapses rose in parkinsonian mice. However, the sCRACm mapping experiments, in which individual synapses were optically stimulated, failed to detect any significant change in the distribution of EPSC amplitudes after lesioning ( Figure 2C ). Moreover, the ratio of a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) currents to N-methyl-D-aspartate receptor (NMDAR) currents evoked by PFn stimulation was similar in iSPNs from control and parkinsonian mice ( Figure S2F ).
Enhanced PFn-Evoked iSPN EPSCs Were Dependent upon ChIs
If the number and strength of PFn synapses on iSPNs were not changed in parkinsonian mice, then alterations in the striatal network activated by PFn stimulation must be responsible for the enhancement in iSPN responses. To test this hypothesis, optical approaches were used in ex vivo brain slices in which network activity was eliminated by bath application of the Na + channel blocker tetrodotoxin (TTX, 1 mM) and synaptic-terminal excitability was enhanced with 4-aminopyridine (4AP, 100 mM). In this state, optical stimulation of ChR2 can be used to isolate postsynaptic responses in the absence of conducted network activity (Petreanu et al., 2009) (Figure 2D ). In this preparation, PFn-evoked EPSCs in iSPNs and dSPNs were smaller, as expected (Figures 2E and S2G Although PFn neurons are capable of engaging a variety of striatal circuits (Assous et al., 2017; Doig et al., 2014; Lapper and Bolam, 1992) , the experiments described thus far were conducted in the presence of GABA A and GABA B receptor antagonists, eliminating a role for GABAergic circuits. Another potential mediator of this network-driven amplification of PFn responses in iSPNs is the ChI, which is robustly innervated by PFn neurons (Ding et al., 2010; Doig et al., 2014; Lapper and Bolam, 1992; Sadikot et al., 1992) . As a first step toward testing this hypothesis, the PFn-evoked responses in ChIs were measured in ex vivo Representative traces showing PFn-EPSCs before and after bath application of TTX (1 mM) and 4AP (100 mM) (left). PFn-EPSC areas (pC) were plotted against laser intensity in each condition (right). (E) Control; before versus TTX + 4 AP (laser power [mW]): p = 0.0313 (8.35), p = 0.0313 (6.25), p = 0.0313 (4.41), p = 0.125 (2.04), p = 0.25 (0.98), sign rank test. n = 14, N = 7. (F) Parkinsonian; before versus TTX + 4 AP (laser power [mW]): p = 0.031 (8.35), p = 0.031 (6.25), p = 0.031 (4.41), p = 0.031 (2.04), p = 0.063 (0.98), sign rank test. n = 10, N = 4. (E and F) control (TTX + 4AP) versus parkinsonian (TTX + 4AP) at maximum laser power (8.35 mW), p = 0.230, rank sum test. (G) Schematic of recording of PFn-EPSCs from ChI in Grp-KH288 mouse injected with Cre-off ChR2-eYFP into the PFn. (H) Input-output relationship of PFn-EPSCs in ChIs from control and parkinsonian. Representative traces showing PFn-EPSCs in ChI from control (black) and parkinsonian (red) mice (left). PFn-EPSC areas (pC) were plotted against laser intensity (right). Control versus parkinsonian (laser power [mW]): p = 0.007 (8.35), p = 0.002 (6.25), p = 0.006 (4.41), p < 0.001 (2.04), p = 0.006 (0.98), rank sum test. Control: n = 26, N = 7. Parkinsonian: n = 30, N = 9. (I) Effect of TTX and 4AP on PFn-EPSCs in ChIs from control and parkinsonian mice. Representative traces showing PFn-EPSCs in ChI before and after bath application of TTX and 4AP (left). Boxplots of EPSC areas with or without TTX and 4AP from control and parkinsonian mice (right). Median charge in control (pC): before, 253.79; TTX + 4AP: 421.22, n = 10, N = 4. Median charge in parkinsonian (pC): before, 869.44, TTX + 4AP: 1486.6, n = 7, N = 4. Control (TTX + 4AP) versus parkinsonian (TTX + 4AP); p < 0.001, rank sum test. slices from control and parkinsonian mice in the presence of the muscarinic receptor (mAChR) antagonist atropine (10 mM) and the nAChR antagonist mecamylamine (10 mM) to blunt activity propagated from the ChIs themselves ( Figure 2G ). PFn-evoked EPSCs in ChIs were clearly enhanced in the parkinsonian tissue ( Figure 2H ). In contrast to iSPN responses, the enhancement of PFn-evoked EPSCs in ChIs in tissue from parkinsonian mice was not eliminated by blocking network activity with TTX, suggesting that PFn synapses on ChIs were stronger or more numerous in parkinsonian mice ( Figure 2I ). In fact, PFn-evoked responses in ChIs were enhanced by blocking propagated network activity. Although there are alternative interpretations of this result, the most parsimonious one is that network activity was actually dampening the PFn-evoked response in ChIs.
Could ChIs be responsible for the enhancement of PFnevoked EPSCs in iSPNs? To test this hypothesis, we used a chemogenetic approach. The inhibitory hM4D designer receptor activated by designer drug (DREADD) (Ferguson et al., 2011) was expressed in ChIs by AAV delivery of a Cre-dependent expression construct into the striatum of bi-transgenic mice expressing Cre recombinase in choline acetyltransferase (ChAT) neurons (ChAT-Cre) and eGFP in D2R-expressing neurons. In these mice, an AAV carrying a ChR2-eYFP expression construct was also injected into the PFn ( Figure 3A ). The agonist for the hM4D, clozapine-N-oxide (CNO, 1 mM), suppressed spontaneous spiking of hM4D + ChIs in slices from hM4D-injected mice but did not affect spiking of ChIs in un-injected mice (Figures S3A-S3C) . To test the hypothesis that ChIs were necessary for the enhancement of PFn-evoked EPSCs in iSPNs, we examined the effect of CNO in slices from parkinsonian mice (Figure 3B) . Indeed, CNO reduced PFn-evoked EPSCs in iSPNs by approximately 40% in tissue from infected mice ( Figure 3C ) but did not affect the response in tissue from control mice ( Figure S3D ).
Because ChIs can release glutamate (Higley et al., 2011; Nelson et al., 2014) , one interpretation of this result is that ChIs are directly activating postsynaptic iSPN glutamate receptors. To test this hypothesis, ChAT Cre mice were used to selectively express ChR2-eYFP in ChIs, and then ChIs were optogenetically activated while recording from iSPNs in ex vivo slices from control and parkinsonian mice ( Figure 3D ). As expected, ChI-evoked inward currents were found in iSPNs. These currents were sensitive to an AMPAR antagonist (NBQX, 10 mM) and to a cocktail of nAChRs antagonists (the a4b2* antagonist, dihydro-b-erythrodine [DHbE], 1 mM) and methyllycaconitine (MLA, 100 nM), which antagonizes a7 and a6b2* nAChRs (where * indicates the possible inclusion of other subunits) ( Figure 3E ). However, there was no difference in the magnitude of these currents in iSPNs from control and parkinsonian tissue ( Figure 3E ). Moreover, these currents were too small to account for the increase in PFn-evoked EPSCs in iSPNs, even with synchronous activation of ChIs.
Another way in which ChIs might enhance PFn-evoked responses in iSPNs is through postsynaptic M1 mAChR signaling (Shen et al., 2007) . M1 mAChR-mediated downregulation of dendritic Kir2 and Kv7 K + channels could enhance PFn-evoked ) and NBQX (10 mM) (left). Boxplots represent peak amplitudes of ChI-EPSCs in iSPNs before and after bath application of DHbE and MLA from control and parkinsonian mice (right). Median ChI-EPSC peak amplitudes in control (pA): before, 29; DHbE + MLA, 17.1; p = 0.0039, sign rank test; n = 9; N = 4. Median ChI-EPSC peak amplitudes in parkinsonian (pA): before, 38.2; DHbE + MLA, 28.8; p = 0.002, sign rank test; n = 10; N = 4. Control (before) versus parkinsonian (before): p = 0.1212; control (DHbE + MLA) versus parkinsonian (DHbE + MLA): p = 0.1128, rank sum test. excitatory postsynaptic potentials (EPSPs) in iSPNs. However, in the experiments described thus far, the patch pipette was filled with Cs + to block K + channels, minimizing any contribution of this signaling pathway to the enhancement of PFn responses. Nevertheless, the effect of the broad-spectrum mAChR antagonist (atropine [10 mM]) was examined. Atropine had no effect on PFn-evoked EPSCs in iSPNs from parkinsonian mice (Figures S3E and S3F) .
Presynaptic a6b2* nAChRs Mediated the Enhancement of PFn Responses Because nAChRs are not expressed in SPNs (Jones et al., 2001; Zhou et al., 2002) , a third possibility was that ChIs were enhancing the release of glutamate at PFn terminals by activation of nAChRs (McGehee et al., 1995) . Thalamic neurons, including those in the PFn, robustly expressed several nAChR subunits, including a4, a6, and b2 subunits (Hill et al., 1993; Parker et al., 2004; Wada et al., 1989) . Indeed, the broad-spectrum nAChR antagonist, TMPH (50 mM), significantly reduced PFn-evoked EPSCs in iSPNs from parkinsonian mice ( Figure 4A ). Moreover, nicotine at a concentration (500 nM) that should desensitize nAChRs (Chung et al., 2016; Quick and Lester, 2002) reduced PFn-evoked EPSCs in iSPNs from control and parkinsonian mice, but not in dSPNs ( Figure S4A ).
To determine the type of nAChR involved, we used both pharmacological and molecular strategies. The a6b2* blockers, a conotoxin MII (Con. MII, 100 nM) and a conotoxin PIA (ConPIA, 10 nM), both reduced PFn-evoked EPSCs in iSPNs of parkinsonian mice ( Figures 4B and 4C) , much as did MLA (another a6b2* nAChR antagonist); MLA had no effect on PFn-evoked responses in dSPNs ( Figures S4B and S4C) . In contrast, the a4b2* antagonist DHbE (1 mM) and the a7 antagonist a-bungarotoxin (a-BTX, 100 nM) had no effect on PFn-evoked EPSCs in iSPNs from parkinsonian mice ( Figure 4C ). Taken together, these results suggest that presynaptic a6b2* nAChRs were responsible for the ChI-mediated enhancement of PFn-evoked EPSCs in iSPNs. To complement these pharmacological strategies, a genetic approach was used to selectively knock down (KD) a6 mRNA in PFn neurons; this was achieved by injecting an AAV carrying a6 shRNA-tdTomato construct into the PFn of D2-eGFP parkinsonian mice ( Figure S4D ). The KD was verified by qPCR analysis ( Figure S4E ). As predicted, PFn-evoked EPSCs in parkinsonian mice with a6 KD were significantly reduced ( Figure 4D ). Furthermore, the effect of the a6b2 selective antagonist, Con.PIA, was abolished by a6 KD (Figure 4E ). In contrast, injection of an AAV with a scrambled shRNA construct had the same effect of Con.PIA on PFn-evoked EPSCs in iSPNs from parkinsonian mice ( Figure 4E ). Collectively, these results support the proposition that presynaptic, a6-containing nAChRs mediate the amplification of PFn-evoked responses in iSPNs from parkinsonian mice. If ChIs were enhancing glutamate release from PFn terminals, then nAChRs should increase the release probability at PFn-iSPN synapses. To test this prediction, we measured the iSPN response to paired PFn pulses and computed their ratio (Cheng and Yakel, 2014; Fioravante and Regehr, 2011) . Because ChR2 cannot be used to reliably stimulate axons at the frequency necessary for these assays, these experiments were performed with Chronos, which can follow higher stimulation frequencies (Klapoetke et al., 2014 ). An AAV vector was used to deliver a Cre-independent Chronos-tdTomato expression construct into the PFn of D1-tdTomato/D2-eGFP mice ( Figure 5A ). To test frequency following, whole-cell recordings were made from infected PFn neurons; indeed, spikes were reliably evoked by brief light pulses at up to 20 Hz ( Figure 5B ). Next, to evoke conducted spikes (and avoid the complication of opsin activation in PFn-iSPN terminals), a small laser spot ($10 mm diameter) was positioned $400 mm away from the somatic recording electrode. Measured in this way, the paired-pulse ratio (PPR) was near 1 at 15 Hz in control iSPNs, but significantly less than one in parkinsonian iSPNs ( Figure 5C ). MLA (100 nM) increased the PFn PPR values in iSPNs from parkinsonian mice into a range that was indistinguishable from that of control mice ( Figure 5C ). These results suggest that the activation of nAChRs increased the release probability at PFn-iSPN terminals in parkinsonian mice ( Figure 5D ).
One potential complication in the interpretation of these experiments is that the opsin expression construct could have spread from the PFn injection site to the CLn. To assess whether CLn terminals might also be sensitive to manipulation of nAChRs, a Cre-on AAV ChR2 expression vector was injected into the CLn of Grp-KH288 mice (Figures S5A and S5B) and two experiments were performed ( Figures S5C and S5D) . First, the ability of the acetylcholine esterase inhibitor ambenonium (10 nM) to enhance the CLn response was tested. Ambenonium had no effect on the CLn-evoked responses in iSPNs (Figure S5D) . Second, the sensitivity of the CLn-evoked response to nAChR antagonist TMPH (50 mM) was tested. TMPH had no effect on the response of iSPNs ( Figure S5D) . These results suggest that axospinous CLn synapses on iSPNs, in contrast to axodendritic PFn terminals, do not have nAChRs that modulate glutamate release.
A common effect of activating presynaptic nAChRs is an augmentation of transmitter release (Dani, 2001; MacDermott et al., 1999) . To assess changes in single release events, we replaced extracellular Ca 2+ with Sr 2+ (5 mM) and optogenetically stimulated PFn axons. Indeed, the amplitude distribution of Sr 2+ mEPSCs was shifted toward larger values in parkinsonian mice and this shift was reversed by bath application of the nAChR antagonist mecamylamine ( Figures 5E-5H ).
Synaptic Amplification Was Attributable to Enhanced ACh Release
The most straightforward way to increase ACh responsiveness would be to increase terminal expression of nAChRs. To test this hypothesis, the abundance of nAChR subunit mRNA was compared in control and parkinsonian PFn tissues by qPCR. This analysis failed to find any change (data not shown). However, as PFn neurons are heterogeneous (Beatty et al., 2009; Lacey et al., 2007) , it could be that the upregulation was limited to a sub-population of PFn neurons that innervated iSPNs, making it difficult to detect in pooled PFn tissue. This idea is consistent with the observation that, in contrast to iSPNs, the response of ChIs to PFn stimulation was not sensitive to nAChR antagonists (data not shown). One prominent sub-population of PFn neuron expresses Rbp4 (http://www.gensat.org/cre.jsp), which is absent from neighboring CLn neurons ( Figure S6A ). To determine whether Rbp4-expressing (Rbp4 + ) PFn neurons differentially innervated SPNs and ChIs, a Cre-dependent AAV carrying a ChR2-eYFP expression construct was injected into the PFn of mice expressing Cre recombinase under the control of the Rbp4 promoter ( Figure 6A ) and optogenetic approaches were used to assess connectivity. Indeed, optogenetic stimulation of Rbp4 + PFn axons evoked significantly larger responses in SPNs than in neighboring ChIs ( Figure 6B ). This response pattern is the opposite of that seen when all PFn neurons were induced to express ChR2 by injecting a Cre-off vector into the PFn of Grp-KH288 mice ( Figure 6C ); in this situation, the PFn-evoked EPSC in ChIs was significantly larger than that in SPNs (Figure 6D) . Thus, Rbp4 + PFn neurons preferentially innervate SPNs, whereas Rbp4-lacking (Rbp4 À ) PFn neurons preferentially innervate ChIs ( Figure S6B ).
To determine whether Rbp4 + PFn neurons upregulated nAChR-subunit expression in parkinsonian mice, we used an AAV vector to deliver a Cre-on RiboTag-tdTomato expression construct into the PFn of Rbp4 Cre mice ( Figure 6E) (Sanz et al., 2009 ). The mRNA from Rbp4 + PFn neurons in control and parkinsonian mice was isolated and subjected to qPCR analysis. However, as with pooled PFn tissue, there were no significant alterations in the expression of a6, a4, or b2 mRNA in Rbp4 + PFn neurons in parkinsonian mice ( Figure 6F ). Another possibility was that PFn-evoked ACh release was elevated in parkinsonian mice. There are several ways in which this might happen. As noted above, PFn synapses on ChIs were strengthened following 6-OHDA lesioning, potentially increasing the evoked spiking and ACh release. In addition, previous work has shown that diminished autoreceptor function and loss of tonic, inhibitory presynaptic signaling through D2Rs on ChI terminals contribute to increased ACh release in the parkinsonian striatum . To determine if loss of D2R signaling was a factor in the amplification of PFn-evoked responses, the D2R agonist quinpirole was bath applied to ex vivo slices while optogenetically stimulating PFn axons and recording from voltage-clamped, Cs + filled iSPNs (blunting any postsynaptic effects of quinpirole). Indeed, quinpirole reduced PFn-evoked EPSCs in iSPNs from parkinsonian mice ( Figures 6G and 6H) . Taken together, these results suggest that increased release of ACh was a major factor driving the amplification of PFn-evoked responses in iSPNs from parkinsonian mice.
Suppressing the PFn-Striatal Circuit Alleviated Motor-Learning Deficits in Parkinsonian Mice
If the alterations in the PFn circuitry contributed in a substantive way to the imbalance between iSPN and dSPN activity in the parkinsonian mice, then attenuating these alterations should ameliorate parkinsonian motor deficits. As a first step toward testing this hypothesis, the Cre-dependent hM4D vector was injected, along with an AAV carrying a ChR2 expression construct, into the PFn of Rbp4 Cre mice. In ex vivo slices from these mice, CNO (1 mM) reduced PFn-evoked EPSCs, demonstrating the efficacy of the approach to reduce transmission in the PFn pathway ( Figures S7A-S7D ). Next, the impact of suppressing Rbp4 + neurons on motor performance was examined. One commonly used assay of motor performance is the rotarod (Figure 7A 1 ). As previously reported Carvalho et al., 2013) , parkinsonian mice have a great deal of difficulty with this test (Figures 7A2-7A6 ). However, chemogenetic suppression of PFn Rbp4 + neurons following intraperitoneal injection of CNO (0.5 mg/kg) dramatically improved the ability of parkinsonian mice to stay on the rod over successive days when the rod was turning at a constant speed ( Figure 7A 3 ) . At the end of the training period, mice were tested for their ability to stay on the rod as its speed was increased. In this task, CNO-treated parkinsonian mice performed almost as well as un-lesioned control mice (Figure 7A 6 ). This effect on behavior was mimicked by KD of a6 mRNA in PFn and by chemogenetic suppression of ChIs ( Figures 7A 4 -7A 6 ). CNO treatment of parkinsonian mice lacking hM4D expression had no effect on motor performance (Gomez et al., 2017) (Figures 7A 2 and A 6 ). Chemogenetic inhibition of Rbp4 + PFn neurons and ChIs or KD of a6 mRNA in PFn also restored the ability of parkinsonian mice to learn to descend a vertical pole when placed at its highest point ( Figure 7B) . As with the rotarod, there is a clear learning component to this task and it is not simply an assay of the ability to move (Doeppner et al., 2014) . In contrast to these motorlearning tests, exploratory activity in an open field and gait control were not significantly improved by chemogenetic suppression of PFn Rbp4 + neurons or a6 KD in PFn (Figures S7E-S7I ). As previously reported (Maurice et al., 2015) , there was a modest improvement in open-field behavior by chemogenetic suppression of ChIs in parkinsonian mice ( Figures S7E and S7F) , suggesting that ChIs play multiple roles in movement control.
DISCUSSION
Our results demonstrate that, in a mouse model of late-stage PD, there are significant alterations in the functional connectivity of the PFn with the striatum, which contribute to the imbalance between the excitability of striatal output pathways and the motor deficits associated with the disease. Specifically, (F) Abundance of nAChR subunits mRNA in control and parkinsonian mice. a6; control versus parkinsonian: p = 0.2. a4; control versus parkinsonian: p = 0.48, b2; control versus parkinsonian: p = 0.48; N = 4, rank sum test. (G) Schematic diagram of presynaptic D2 receptor-mediated ACh release from ChI terminal. (H) Effect of quinpirole on PFn-EPSCs in iSPN of parkinsonian mice. Representative traces of PFn-EPSCs in iSPN before and after bath application of quinpirole (10 mM) (left). Boxplots represent peak amplitudes of PFn-EPSCs in iSPN before and after bath application of quinpirole (right). Median peak amplitude of EPSC (pA): before, 199.15; quinpirole, 150.9; p = 0.0078; n = 8; N = 3, sign rank test. our results demonstrate that, although there were no changes in the strength of axodendritic PFn synapses on either iSPNs or dSPNs in parkinsonian mice when viewed in isolation, ChIs enhanced glutamate release at PFn terminals on iSPNs-but not dSPNs-by engaging presynaptic a6-containing nAChRs. Consistent with the proposition that this presynaptic amplification of PFn-mediated excitation of iSPNs contributed to disease symptoms, chemogenetic suppression of this pathway or KD of a6 nAChR mRNA in PFn neurons alleviated motor-learning deficits in parkinsonian mice.
ChIs Enhanced Glutamate Release at PFn Synapses on iSPNs in a PD Model
Lesioning dopaminergic neurons induced a striking enhancement in the response of iSPNs-though not in that of dSPNsto optical stimulation of PFn axons induced to express opsins using a Cre-off expression construct in Grp-KH288 mice. This was evident both in paired recordings from neighboring neurons as well as in the plots of EPSC amplitude as a function of optical stimulus intensity. This result differs from that of Parker et al. (2016) and is attributable to our ability to selectively stimulate PFn neurons because the functional connectivity of CLn neurons with dSPNs is reduced in the parkinsonian state (A.T. et al., unpublished data) . Several observations suggest that the enhanced iSPN response to stimulation of PFn axons was not due to a simple elevation in the number or strength of the PFn synapses. Firstly, there was no change in the number of PFn appositions on iSPN dendrites. Secondly, there was no change in the relative amplitude of AMPAR and NMDAR currents typical of conventional forms of synaptic plasticity (Kauer et al., 1988; Muller and Lynch, 1988; Ungless et al., 2001) . And thirdly, bath application of TTX, which eliminates network activity but preserves the ability of opsins to induce terminal transmitter release in the presence of 4AP, completely eliminated differences in PFn-evoked responses from iSPNs in control and parkinsonian mice. The ChI was a key node in the striatal network mediating the amplification of the iSPN response to stimulation of PFn axons. Three lines of evidence support this conclusion. Firstly, in parkinsonian mice, PFn coupling to ChIs was increased, and chemogenetic suppression of ChIs decreased the amplitude of EPSCs in iSPNs evoked by optogenetic activation of PFn axons. Secondly, in parkinsonian mice, the response of iSPNs to activation of PFn axons was attenuated by D2R agonists, which are known to inhibit ACh release from ChIs (Ikarashi et al., 1997) . Thirdly, in parkinsonian mice, the release of glutamate at PFn synapses on iSPNs was robustly enhanced by presynaptic nAChRs, which are known to exert similar effects in a variety of other neurons (Dani, 2001) . This final inference was based upon: (1) the ability of the broad-spectrum nAChR antagonist TMPH to normalize the amplitude of PFn-evoked EPSCs in iSPNs from parkinsonian mice, (2) the ability of the nAChR antagonist mecamylamine to normalize the amplitude of PFn-evoked Sr 2+ mEPSCs in iSPNs in parkinsonian mice, (3) the ability of the a6b2* nAChR antagonist MLA to normalize the PPR of PFn synapses onto iSPNs from parkinsonian mice, and (4) the ability of a6 nAChR mRNA KD to normalize PFn-evoked EPSCs in iSPNs from parkinsonian mice. In addition to earlier work demonstrating the expression of pre-synaptic a6b2-containing nAChRs in the thalamus (Bohr et al., 2005; Hill et al., 1993; Parker et al., 2004; Wada et al., 1989) , their involvement on PFn terminals is consistent with the ability of conotoxin MII and PIA, but not with that of DHbE or a-BTX, to reduce PFn-evoked EPSCs in iSPNs. Given the stability of thalamic nAChR subunit expression in the parkinsonian state, the most parsimonious interpretation of our data is that the enhancement of PFn-evoked responses in iSPNs was due to increased ACh release in parkinsonian mice (Abercrombie and DeBoer, 1997; Ding et al., 2006) , but it is also possible that cholinergic synapses on iSPN PFn terminals proliferated in this state .
Although the synchronous, optogenetic activation of PFn axons made it appear that the cholinergic modulation of PFn terminals on iSPNs was working in a feedforward manner, this is probably not how this circuitry operates in vivo. Our studies show that the PFn neurons innervating iSPNs and ChIs are largely distinct, with Rbp4 + PFn neurons preferentially coupling to SPNs. This differential coupling suggests that the thalamostriatal PFn circuitry is more likely to act as a coincidence detector. That is, in vivo, the nAChR-mediated presynaptic enhancement in glutamate release will require the coincidence of spiking in Rbp4 + PFn neurons innervating iSPNs and Rbp4 À PFn neurons innervating ChIs. The events driving activity in these two pathways are unclear at this point. It is also possible that other forebrain structures, like the cingulate cortex, which are robustly coupled synaptically to ChIs, may engage this circuitry to amplify thalamostriatal excitation of iSPNs.
Signaling through nAChRs Contributed to PD Symptoms
A cornerstone of current thinking about PD is that the cardinal motor symptoms arise from an imbalance in the excitability of iSPNs and dSPNs (Albin et al., 1989) . This imbalance has long been attributed to the loss of inhibitory D2R signaling in iSPNs and excitatory D1R signaling in dSPNs. However, as shown here, there are a range of secondary effects of DA depletion on the striatal circuitry that can contribute in a substantive way to this imbalance. As noted above, the best-characterized of these are mediated by ChIs. ChIs play an instrumental role in set-shifting or re-directing behavior when expected goals are not being achieved (Bradfield et al., 2013; Brown et al., 2010; Ding et al., 2010) . The ability of ChIs to elevate the excitability of iSPNs and to lower that of dSPNs through complementary mAChRs fits perfectly with this role and mirrors the dichotomy in DA effects (Bernard et al., 1992; Shen et al., 2015; Shen et al., 2007; Yan et al., 2001) . The engagement of ChIs in set-shifting is regulated by PFn neurons responding to salient sensory events (Aoki et al., 2015; Bradfield et al., 2013; Groenewegen and Berendse, 1994; Kato et al., 2011; Matsumoto et al., 2001) . SNc dopaminergic neurons can gate this set-shifting signal by inhibiting ChIs (Deng et al., 2007; Maurice et al., 2004; Yan et al., 1997) . However, with PD progression and the degeneration of SNc dopaminergic neurons, this gating is lost, leading to unregulated coupling of salient sensory events to ChI modulation of striatal circuits. This situation may be exacerbated by an elevation in the excitability of PFn neurons (Parr-Brownlie et al., 2009 ) and, as shown here, by the strengthening of synaptic coupling between PFn neurons and ChIs. Thus, the imbalance in striatal efferent pathways stems from both the loss of dopaminergic signaling and the augmentation of that arising from ChIs.
Although the importance of cholinergic signaling through mAChRs to the striatal imbalance and PD symptoms has long been recognized (Lim et al., 2014; Pisani et al., 2007; Tanimura et al., 2018) , the importance of nAChRs has not. Our studies demonstrate that nAChRs contribute to the PD state itself, showing that either chemogenetic suppression of the PFn pathway or KD of a6 mRNA in the PFn alleviate motor-learning deficits accompanying the parkinsonian state in mice. Even though the initial motor performance of parkinsonian mice was poor, suppressing the thalamostriatal-circuit-targeting nAChRs enabled mice to become progressively better at staying on a rotarod or descending a pole, so that by the end of training, these mice were nearly as good at the task as un-lesioned mice. In contrast to these motor-learning tasks, exploratory open-field behavior, which has no direct learning component, was unaffected by manipulating the PFn pathway and was only modestly improved by suppressing ChIs, in agreement with previous work (Maurice et al., 2015) . Our results are consistent with previous work demonstrating that high-frequency, deep-brain electrical stimulation (DBS) of the PFn significantly diminishes motor disability and molecular signs of indirect pathway hyperactivity in a rodent model of PD (Jouve et al., 2010) , as does PFn lesioning (Kerkerian-Le .
It remains to be determined precisely how suppressing the PFn circuit enabled motor learning in severely parkinsonian mice. Our working hypothesis is that suppressing the thalamostriatal network restored balanced activity in iSPNs and dSPNs, complementing homeostatic mechanisms that target cell-autonomous effects of dopamine depletion (Day et al., 2006; Fieblinger et al., 2014; Smith et al., 2004) . Although restoring balanced excitability in striatal efferent pathways will not enable striatal learning, it should minimize aberrant basal ganglia output and motor disability, allowing other motor control circuits to take over action learning. In this regard, it is important to note that in humans with PD and in primate models of PD, there is a modest loss of PFn neurons (Surmeier et al., 2017; Villalba et al., 2014) (which is not recapitulated in the rodent 6-OHDA lesion model (Kusnoor et al., 2009; Parker et al., 2016) ). Our results suggest that this PFn loss could be adaptive.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: at À70 mV in recording from SPNs and at À60 mV in recording from ChIs. Liquid junction potential was not corrected. a-bungarotoxin, a-conotoxin MII and a-conotoxin PIA is applied with ACSF including bovine serum albumin (0.2 mg/mL). All compounds were purchased from TOCRIS and SIGMA.
Optogenetics
To activate ChR2 containing axons in the dorsolateral striatum, a 473nm laser photo-stimulation system using a CrystaLaser (safety protocols for Class 3B laser) has been added on top of an existing Olympus BX 50 WI upright microscope (Kress et al., 2013) . The system can produce a central laser spot with moderate diameter ($10 mm) or sub-mm spot size in conjunction with an objective lens. A physical hard shutter (Uniblitz LS3Z2), with 2 ms response time, is included in the laser path to minimize exposure doses when not running a photo-stimulation experiment. The sample power is controlled by an electro-optical voltage controlled Pockels' cell modulator (ConOptics; Danbury, CT). A scaled voltage is recorded from a photo-diode (S2245-44K, Thorlabs) signal which is proportional to the delivered sample laser power. A single system computer controls the camera as well as the laser power, modulator transmission, and fast shutter. For whole field stimulation, larger sample spot size (700 mm diameter) is created by expanding the laser beam with a 2.5 X simple beam expander (50 mm fl and 125 mm fl lenses, 175 mm apart), then the laser beam is routed down through the Olympus system tube lens (180 mm fl) to focus into the entrance pupil of the 5X objective lens (0.15 NA) .
Smaller sample spot size (10 mm) was created with an additional lens inserted after the above beam expander. The third lens, with 75 mm fl, was set 255 mm away from the tube lens to create an additional 2.4 X (180 mm/75 mm) simple beam expansion-with collimated light now filling and entering the objective lens; this creates a sub-mm diameter spot at the 5 x objective lens (0.15 NA) focus. Blue light pulses (5 ms duration) were given to slice surface.
The EPSC peak amplitudes were averaged for three to five, with an inter sweep interval of 30 to 50 s. Representative traces showing EPSCs evoked by maximum intensity stimulation (8.35 mW, 5 ms).
Open filed test; Activity in the open field (56 cm 3 56 cm box) for 5 min was tracked using LimLight software (ACTI METRICS). For chemogenetically-modified mice, at day1, mice were treated with saline or CNO 30 min before test. Two days later, open field test was repeated and the saline/ CNO treatment were switched. Total distance traveled was measured.
DigiGait; After a brief acclimation period, the mouse was placed in the arena and the treadmill started. The belt speed stayed between 5 and 80 cm/sec. Lower speeds were used for animals with impaired gaits. Speed for analysis was 10 cm/sec. A testing session lasted for approximately 5 min in order to collect several bouts (4 s) of gait that were interspersed with periods of rest.
QUANTIFICATION AND STATISTICAL ANALYSIS
Data Analysis
Data analysis was performed with Clampfit 10.3 (Molecular Devices, Inc.), Igor Pro 5.0 (WaveMetrics, Lake Oswego, OR), MATLAB R2017b (Mathworks, Natick, MA) and Python. Peak amplitude of Sr 2+ induced asynchronous miniature EPSCs were pseudo-automatically measured using custom routine (Python), after subtracting best-fitted exponential curve from original traces. Events were measured between 20 ms after photostimulation to 500 ms. The threshold for detection of an event was greater than 5 SD above the noise.
Statistical analyses were performed using MATLAB. Data were represented as median and first and third quartiles. Box and whisker plots show median, first/third quartiles, and maximum/minimum values. Lines were obtained by polynomial curve fitting. Statistical evaluations were performed using non-parametric rank sum test. When sample show normal distribution, t test was applied. For paired data, sign rank test was performed. For multiple group comparison, Kruskal-Wallis test was performed. For analysis of cumulative probability, non-parametric Kolmogorov-Smirnov test (KS test) was applied. For analysis of rotarod in training periods, two-way ANOVA was performed. ''n'' indicated cell number, ''N'' indicated animal number.
DATA AND SOFTWARE AVAILABILITY
Gene expression data of Grp-KH288 and Rbp4-KL100 are available at http://www.gensat.org/cre.jsp.
